The clock is running on two separate fronts for Diginex, and each one carries existential weight. The company’s stock is clinging to $1.03 — barely above the Nasdaq $1.00 minimum bid price — while a June 12 deadline looms for its $1.5 billion acquisition of Resulticks Global Companies. Any stumble on either front could rewrite the narrative entirely.
The Resulticks deal, structured as a full stock swap, would be transformative by any measure. Diginex currently sports a market capitalisation of roughly $34 million and generated just $3.6 million in revenue over the trailing twelve months. Resulticks, meanwhile, is projected to deliver annual revenue of $150 million and EBITDA in the range of $46 million to $50 million. The gap between buyer and target is so wide that if the deal closes, Diginex would effectively become a much larger entity overnight.
That makes the Nasdaq compliance issue all the more urgent. The exchange informed Diginex in March 2026 that its stock had traded below $1.00 for 30 consecutive sessions, triggering a non-compliance notice. The company has 180 calendar days — until September 21, 2026 — to regain compliance. To do so, the stock must close at or above $1.00 for at least ten consecutive trading days. A reverse stock split executed on April 28 at an 8-for-1 ratio was meant to create breathing room, but the shares have since slid back toward the danger zone. Over the past seven sessions the stock has fallen 11.21%, and over 30 days the drop stands at 24.82%. The relative strength index sits at 31.1, signalling an oversold condition that hints at a possible bounce — but provides no guarantee of a sustained recovery.
Should investors sell immediately? Or is it worth buying Diginex?
Inside the boardroom, confidence is being backed by personal capital. Chairman Miles Pelham has invested roughly $25.4 million of his own money into Diginex since its initial public offering, with an average entry price of $5.69 per share — more than five times current levels. That stake serves as a visible vote of faith, though it does nothing to shorten the distance to compliance.
Beyond the deal and the listing risk, Diginex is also laying groundwork in an adjacent market. On June 4, the company integrated its Risk-to-Remedy solution into the platform, combining the LUMEN risk-assessment module with APPRISE for direct employee feedback. The target market: human rights and supply-chain due diligence, estimated at $3.8 billion in 2025 and expected to swell to $9.6 billion by 2034. Regulatory tailwinds — including the UK and Australian Modern Slavery Acts, Canada’s Fighting Against Forced Labour Act, the EU’s CSDDD, and Germany’s Lieferkettensorgfaltspflichtengesetz — are driving the expansion.
The next few days will be decisive. If Diginex fails to satisfy the remaining closing conditions for Resulticks by Friday, the deal could be pushed back again or collapse entirely. If it closes, the company gains a revenue engine that dwarfs its current operations — but must still keep its stock above $1.00 to avoid Nasdaq delisting. For now, every tick matters.
Ad
Diginex Stock: Buy or Sell?! New Diginex Analysis from June 8 delivers the answer:
The latest Diginex figures speak for themselves: Urgent action needed for Diginex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 8.
Diginex: Buy or sell? Read more here...
